Evidence map›Paper›PMID 34928708›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.

Martin R Stockler, Andrew J Martin, Ian D Davis, Haryana M Dhillon, Stephen D Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague and 24 more

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Progress in management of advanced clear-cell renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 13 institutions in 10 countries.

Martin R StocklerNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-3793-8724
Andrew J MartinNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Ian D DavisMonash University, Melbourne, Victoria, Australia.ORCID 0000-0002-9066-8244
Haryana M DhillonCEMPED: The University of Sydney Centre for Medical Psychology and Evidence-Based Decision-Making, Sydney, NSW, Australia.ORCID 0000-0003-4039-5169
Stephen D BegbiePort Macquarie Base Hospital, Port Macquarie, New South Wales, Australia.ORCID 0000-0001-9277-6479
Kim N ChiBC Cancer Agency Vancouver Centre, Vancouver, BC, Canada.ORCID 0000-0002-3782-7226
Simon ChowdhuryGuy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Xanthi CoskinasNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Mark FrydenbergMonash University, Melbourne, Victoria, Australia.
Wendy E HagueNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Lisa G HorvathChris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Anthony M JoshuaKinghorn Cancer Centre, St Vincent's Hospital, Sydney, New South Wales, Australia.ORCID 0000-0001-5159-4580
Nicola J LawrenceAuckland District Health Board, Auckland, New Zealand.ORCID 0000-0003-1545-1923
Gavin M MarxSydney Adventist Hospital, Sydney, NSW, Australia.
John McCaffreyCancer Trials Ireland, Dublin, Ireland.ORCID 0000-0002-0179-9067
Ray McDermottSt Vincent's University Hospital, Dublin, Ireland.
Margaret McJannettANZUP Cancer Trials Groups, Sydney, NSW, Australia.
Scott A NorthCross Cancer Institute, Edmonton, Alberta, Canada.
Francis ParnisAdelaide Cancer Centre, Adelaide, South Australia, Australia.
Wendy R ParulekarCanadian Cancer Trials Group, Kingston, Ontario, Canada.ORCID 0000-0002-6007-7494
David W PookMonash Health, Melbourne, Victoria, Australia.ORCID 0000-0002-1744-3022
M Neil ReaumeUniversity of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-9214-222X
Shahneen SandhuPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-8660-4475
Alvin TanWaikato District Health Board, Hamilton, New Zealand.
Thean Hsiang TanRoyal Adelaide Hospital, Adelaide, South Australia, Australia.
Alastair ThomsonRoyal Cornwall Hospital, Cornwall, United Kingdom.
Francisco Vera-BadilloKingston Health Sciences Centre, Kingston, Ontario, Canada.ORCID 0000-0003-1068-3258
Scott G WilliamsPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-1357-0884
Diana G WinterNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Sonia YipNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Alison Y ZhangNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Robert R ZielinskiOrange Health Service, Orange, New South Wales, Australia.ORCID 0000-0002-4807-8523
Christopher J SweeneyDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-0398-6018
ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Janssen (Belgium) · BEThe University of Sydney · AUPeter MacCallum Cancer Centre · AUBC Cancer Agency · CACentre for Cancer Biology · AUDana-Farber Cancer Institute · USKingston Health Sciences Centre · CAMonash Health · AURoyal Adelaide Hospital · AURoyal Cornwall Hospital · GBUniversity of Ottawa · CAWaikato District Health Board · NZWestern NSW Local Health District · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL).

methodsHRQL was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression. Scores from week 4 to 156 were analyzed with repeated measures modeling to calculate group means and differences. Deterioration-free survival was from random assignment until the earliest of death, clinical progression, discontinuation of study treatment, or a worsening of 10 points or more from baseline in fatigue, physical function, cognitive function, or overall health and quality of life (OHQL). HRQL scores range from 0 (lowest possible) to 100 (highest possible).

resultsHRQL was assessed in 1,042 of 1,125 participants (93%). Differences in means favored control over enzalutamide for fatigue (5.2, 95% CI, 3.6 to 6.9;

conclusionEnzalutamide was associated with worsening of self-reported fatigue, cognitive function, and physical function, but not OHQL. Enzalutamide was associated with improved deterioration-free survival for OHQL, physical function, and cognitive function because delays in disease progression outweighed early deteriorations in these aspects of HRQL.

Indexed as

Prostatic Neoplasms, Castration-ResistantQuality of LifeAntineoplastic Combined Chemotherapy ProtocolsFatigueHormonesHumansMaleNitrilesHormonesNitriles

Identifiers

PMID34928708
PMCPMC8906451
OpenAlexW4200095907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.